Polypid Ltd Dossier
Qualitative Analysis
Business overview
PolyPid Ltd. (Nasdaq: PYPD) is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of innovative, locally administered, controlled-release therapeutics. The company's proprietary Polymer-Lipid Encapsulation MatriX (PLEX) technology platform is designed to encapsulate active pharmaceutical ingredients (APIs) to enable targeted, localized drug delivery directly at the site of care over extended periods with pre-determined release rates. PolyPid's lead product candidate is D-PLEX100, a localized, long-acting formulation of the broad-spectrum antibiotic doxycycline designed for the prevention of surgical site infections (SSIs) following abdominal colorectal surgeries. Additionally, the company is developing OncoPLEX, an intra-tumoral therapy candidate for solid tumors, and exploring ultra-long-acting formulations for metabolic diseases such as GLP-1 receptor agonists.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
PolyPid is actively engaged in late-stage negotiations to secure a strategic commercial partner in the United States with a robust hospital network to execute the commercial launch of D-PLEX100.
Expected impact: Facilitates rapid market penetration into the U.S. hospital network, targeting a total addressable market of 4.4 million annual abdominal surgeries.
Plans to expand the clinical indications of D-PLEX100 beyond colorectal surgery to other types of abdominal and general surgical procedures.
Expected impact: Significantly broadens the addressable patient population and commercial market size.
Broadening the proprietary polymer-lipid encapsulation matrix (PLEX) technology platform, including the development of a long-acting GLP-1 program for metabolic health and intra-tumoral OncoPLEX for oncology.
Expected impact: Diversifies the company's pipeline beyond surgical site infections into high-growth therapeutic areas like metabolic health and oncology.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Critical for executing the commercial launch, marketing, and distribution of D-PLEX100 in the United States.
Terms: Currently in late-stage negotiations; specific financial terms have not been publicly disclosed.